HRA00129 C004
Alternative Names: HRA00129-C004Latest Information Update: 15 Jun 2024
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacodynamics, pharmacokinetics and adverse event data from a preclinical studies in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 09 Sep 2023 Preclinical trials in Solid tumours in China (Parenteral)
- 09 Sep 2023 Jiangsu Hengrui Pharmaceuticals files an IND application with the National Medical Products Administration (NMPA) in China for Solid tumours